



Elisabeth Stampá, Board Member at Medichem and President Medicines for Europe

With more than twenty years in the industry and as an experienced business leader with track record in growing and transforming businesses, Elisabeth serves currently at the Board of Medichem SA. She has been the former CEO of Medichem SA., transforming a pure API company into a competitive vertical integrated player. She held other executive positions at Corporate family business (Medichem SA and the former Combino Pharm SL), having started her career at Laboratorios Esteve. She holds a BSc in Pharmacy (UB, Spain) and a MBA (ESADE, Barcelona, Spain). She also serves on the Board of Trustees at the IQS in Barcelona. Elisabeth has been an active member of international associations throughout her professional career and advocates for legislative changes that improve patient accessibility and strengthen the European industry at a global level.



Paul Neill, Chairperson, Medicines for Ireland, Country Manager, Teva Pharmaceuticals

Paul is the current Chairperson of Medicines for Ireland and also the Country Manager for Teva Pharmaceuticals Ireland. Paul has spend over 20 years in various commercial leadership roles in the Irish generics and biosimilar medicines industry.



Stella Kyriakides, Commissioner for Health and Food safety, European Commission

As European Commissioner for Health and Food Safety, Stella Kyriakides has been leading the Commission's work on the public health response to COVID-19. Commissioner Kyriakides is responsible for a number of initiatives in the area of health aiming to establish a strong European Health Union. These include Europe's Beating Cancer Plan, the implementation of the EU Pharmaceutical Strategy, the proposal for a European Health Data Space and the operationalisation of the EU4Health Programme. She is a strong advocate for mental health. Commissioner Kyriakides is also responsible for the 'Farm to Fork' strategy for sustainable food, covering every step in the transformation of the food chain from production to consumption. Her responsibilities include animal welfare, food safety and animal and

plant health and leading the work to protect plant health and reducing dependency on pesticides. Since February 2022, Commissioner Kyriakides has been at the forefront of EU efforts to support Ukraine and its people in the area of health, including by supporting the protection of the physical and mental health of Ukrainian refugees arriving in Member States. In 2006-2019, she was elected to the Cyprus Parliament for the Democratic Rally party, of which she was the Vice-President for ten years. In 2011, she was appointed Head of the Cyprus Delegation to the Parliamentary Assembly of the Council of Europe (PACE). In 2017, she was elected President of the PACE, the fourth woman to hold this position in the history of the Assembly. She has been an active advocate on patients' rights, and on the rights of cancer patients, founding the first Cypriot breast cancer organisation Europa Cyprus, for which she served as President for over 15 years. She was elected President to the European Breast Cancer Coalition Europa Donna, and served on numerous European patient advocacy and scientific boards. She is the recipient of numerous awards from her community service in Cyprus and globally.



Maja Graf, Associate Director Policy & Market Access, Medicines for Europe

Maja Graf is an Associate Director Policy & Market Access for Medicines for Europe, a trade association representing the pharmaceutical companies supplying the largest share of medicines across Europe and is the voice of the generic, biosimilar and value-added industries. In her role, she focuses on issues such as equitable access to affordable treatments across Europe, achieved by sustainable pharmaceutical market for off-patent medicines and innovation throughout the medicines life cycle, in the form of Value Added Medicines. She holds the Master of Sciences of Pharmacy degree obtained from Faculty of pharmacy, University of Ljubljana. Before joining Medicines for Europe, she worked in the pharmaceutical industry. Medicines for Europe is a leading partner for better healthcare aims to increase the health and wellbeing of all Europeans through better access to high-quality medicines.



Max Newton, Engagement Manager, IQVIA

Max Newton, based in London, England, United Kingdom, is currently a Engagement Manager at IQVIA, bringing experience from previous roles at IQVIA. Max Newton holds a 2014 - 2015 Master's Degree in MSc Drug Discovery & Pharma Management (with Distinction) @ UCL. With a robust skill set that includes Management, Leadership, Derivatives, Public Speaking, Investment Banking and more, Max Newton contributes valuable insights to the industry.



John Darby, Executive Director, Lachman Consultants

John Darby is a goal directed, results-focused executive professional with a strong, global background in quality assurance, compliance, audits, training, and remediation. His 18+ years of experience and keen insight contribute to his ability to identify issues and form innovative solutions and strategies for continued success. Mr. Darby has been responsible for the management, organization, and strategic guidance of global, quality and operations-based training functions. He is proficient in sterile pharmaceutical manufacture, oral solid dose manufacture & API manufacture.



Deirdre Kelly, Vice-chair Medicines for Ireland, Country Manager Ireland and Malta, Consilient Health

Deirdre joined Consilient Health in 2014 to set up the Irish business unit. Since then, Deirdre and the Irish team have successfully launched a range of medicines across CH's key therapeutic areas in both the secondary and primary care settings with new launches in Malta from 2021. Prior to joining Consilient Health, Deirdre spent 13 years at Eli Lilly, most recently as business unit manager responsible for the Osteoporosis, Cardiology, Oncology and Primary Care product portfolios. At Novo Nordisk, she was the lead marketer for growth hormone in the UK & Ireland territories. Deirdre started her career at Nutricia where she held a number of management positions. Deirdre has a BSc (Hons) in Nutrition & Dietetics from Trinity College, Dublin with post graduate qualifications in marketing, health economics and a Diploma from the Institute Of Directors. Deirdre is also the vice chair and board member of Medicines For Ireland trade association, past director of the Irish Medicines Verification Organisation and past president of the Irish Pharmaceutical Managers Institute (2022 / 2023).



Prof Michael Barry, National Clinical Lead, Medicines Management Programme, Ireland (inv)

Prof. Michael Barry is a Consultant Clinical Pharmacologist and Head of the Department of Pharmacology & Therapeutics at the University of Dublin, Trinity College. He is the clinical director of the National Centre for Pharmacoeconomics which conducts pharmacoeconomic evaluations on medicines prior to reimbursement under the Community Drugs schemes in Ireland. He is Past-President (2010-2011) of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). He was a board member of the Health Information and Quality Authority (HIQA) and is a member of a number of National Committees on pricing and reimbursement of medicines. Prof. Barry chairs the New Drugs Committee and the Medication Safety Committee at St. James's Hospital, Dublin. In 2013 he was appointed as Clinical Lead for the new HSE Medicines Management Programme. He is a fellow of the Royal College of Physicians in Ireland and is a specialty trainer for Pharmacology & Therapeutics. His research areas include the cost-effectiveness of high cost drugs including chemotherapeutic agents and biologic drugs, pricing and reimbursement and performance based risk sharing schemes. He has published widely on the cost-effectiveness of medicines in the Irish healthcare setting.



Arnaud Mahéas, Chair of Generic Market Access Committee, Medicines for Europe, Head Public Affairs Europe, Sandoz

Arnaud is the Head of Public Affairs Europe at Sandoz. He is responsible for public and government affairs at the EU and national levels in more than 40 countries. His focus is to expand patient access, regain pricing flexibility, promote smart procurement and resilient supply for generic and biosimilar medicines. Since 2023, he chairs the Generic Medicines Market Access Committee at Medicines for Europe. Arnaud is a highly experienced public affairs professional with a successful track record across multiple industries. He built and led the European public affairs practice at Servier. And prior to joining the healthcare industry 15 years ago, he headed the EU representation of the French national railway company (SNCF) and later managed strategic relations with the EU for the association of the top 100 companies operating in France (AFEP). Arnaud holds a Master of Arts in European Administration and Politics from the College of Europe in Bruges and degrees in European Law and Government Affairs from the University of Rennes and Sciences Po Rennes.



Victor Mendonça, Head of Corporate Affairs, Viatriis

Victor Lino Mendonça is the Head of Corporate Affairs for Viatriis in Europe and Board member of Medicines for Europe. Formerly, he was leading the Health Economics department at Medicines for Europe. He was also Advisor to the Executive Board of INFARMED for almost 8 years and prior to this, was the Advisor to the Health Secretary of State to the Ministry of Health in Portugal. He has more than 20 years of experience in pharmaceuticals sector having also worked in FMCG sector. Victor graduated in Business Administration by Universidade Católica Portuguesa in Portugal.



Olivier Girard, DG HERA, European Commission

Olivier is the Head of Unit for Medical Counter Measures in the Health Emergency Preparedness and Response Authority (HERA) of the European Union since 2022. He joined the European Commission in 2003, after beginning his career as a qualified FR/UK attorney specialising in banking and capital markets in London and in Paris. After having worked on financial services, single market and industrial policies in various functions, he was since 2018 Head of Unit in the Secretariat-general of the Commission in charge of industrial policy, research and innovation and the single market. His focus is on supporting development, manufacturing, access to and supply of medical countermeasures in the EU. He is also in charge of the Critical Medicines Alliance, an industrial alliance for the security of supply of critical medicines in the EU which was set up in April 2024.



Clare Fitzell, Head of Strategic Policy, IPU and member of PGEU Executive Board



Philippe Drechsle, Vice President EU Portfolio, Teva

Economist and certified accountant by education, Philippe has been working in the generics industry for over 20 years in various functions spanning from controlling/finance, demand management, product administration, area management, business development, product portfolio optimization, to special projects such as FMD project lead. He is currently responsible for EU Portfolio, in charge of generics product selection, launches and life-cycle management.

Ellen McGrath, Medicines Shortages Coordination Lead, Health Products Regulatory Authority (HPRA)



Ismail Nayef Khdeir, Amgros

Ismail has more than 13 years of extensive experience in procurement of pharmaceuticals from his time in Amgros I/S, the centralized procurement body for hospital medicines in Denmark. He is specialized in strategically planning and executing EU tenders for pharmaceutical products. His responsibilities encompass collecting vital information on the pharmaceutical market, patent expirations and orchestrating tender processes to optimize cost-effectiveness. Furthermore, he works with integrating MEAT criteria into our tender evaluations, with a special focus on emphasizing initiatives that strengthen supply chain resilience

Sarah Tynan, Business Development, Life Sciences, Irish Development Agency (IDA) (inv)



Emer Cooke, Executive Director, European Medicines Agency

Emer Cooke began her mandate as Executive Director of EMA on 16 November 2020. Ms Emer Cooke has over 30 years of experience in international regulatory affairs, with more than 18 of these in leadership roles. Before taking up her current role, she was the Director responsible for all medical product related regulatory activities at the World Health Organization (WHO) in Geneva between November 2016 and November 2020. Ms Cooke worked at EMA between 2002 and 2016. She joined the Agency as Head of Inspections and became Head of International Affairs in 2009. Prior to that, she was Principal Administrator in the Pharmaceuticals Unit of the European Commission between 1998 and 2002, with responsibility for inter alia, inspections, international activities including enlargement of the EU and selected legislative initiatives. Ms Cooke worked for the European Federation of Pharmaceutical industries and Associations (EFPIA) as Manager of Scientific and Regulatory Affairs from 1992 to 1995 and part time from 1996 to 1998. She also worked part time as an independent pharmaceutical policy advisor, based in the Czech Republic, from 1996 to 1998. Ms. Cooke held a number of roles within the Irish pharmaceutical sector between 1985 and 1990 including two years as a pharmaceutical assessor at the Irish medicines regulatory authority. Ms. Cooke holds a degree in pharmacy and two master's degrees in science and in business administration from Trinity College Dublin, Ireland. She is an Irish national.



Aidan Fry, Director External Communications, STADA

Aidan Fry is Director of External Communications at STADA Arzneimittel. In this role, which he has held since February 2020, Aidan oversees communications with key stakeholders across the group's 120-plus markets and activities encompassing generics, specialty medicines and consumer healthcare products. He also coordinates STADA's participation in key industry associations, including Medicines for Europe and the International Generic and Biosimilar medicines Association. Aidan has more than 20 years of experience in the off-patent medicines sector, including as a co-founder and editor of Generics Bulletin, the industry-leading business-to-business newsletter.



Tom Roane, Vice President, Corporate Engagement & Strategy, Direct Relief

Tom Roane serves as Vice President of Corporate Engagement & Strategy for the global medical relief non-profit Direct Relief, an organization founded over 70 years ago which will provide over \$2 Billion this year in donated medical products to vetted and qualified public hospitals and clinics in over 100 countries around the world, including within Europe and the United States. Roane has over two decade's experience in establishing and managing Rx access and medical support programs in all regions of the world to help underserved patients access their required treatments, as well as 8 years' experience in business development and marketing management with big pharma and start up biotechnology companies. His expertise in the design and implementation of creative and impactful ESG programs have opened

opportunities for drug access for underserved patients with cancer, diabetes, rare disease, and non-communicable diseases. All of the world's largest pharmaceutical corporations have trusted relationships with Direct Relief, which has become the largest global non-profit provider of humanitarian medical relief for the world's at-risk and underserved, including in Ukraine where Direct Relief is working hand in hand with the country's health ministry and other strategic partners in providing into Ukraine many hundreds of tons of requested and required vital medical products.



Adele Paterson, CEO, International Health Partners

As CEO of the global health charity International Health Partners (IHP), Adele leads its work to increase access to essential healthcare products for those in vulnerable and disaster hit communities. Last year, IHP delivered 14.5 million treatments supporting 6.8m people in 31 countries. Under Adele's leadership, IHP has initiated rigorous ways to measure the long-term impacts of its work; quadrupled the number of treatments shipped; established a secure, diverse and growing income stream; and has developed an software business bringing supply chain efficiencies, best practice and impact measurement to product donations. Adele joined IHP after working as head of policy for a financial trade association and prior to this, headed CSR, fundraising and communications for a national regeneration charity. An economics and politics graduate, she started her career as a political researcher, running the parliamentary office of a UK government minister. Adele is Treasurer of Integral Alliance, a union of 22 global disaster response agencies, and sits on the Board of the Anglican Communion Fund supporting the international ministry of the Archbishop of Canterbury in 165 countries.



Kate O'Regan, Head of Communications and Stakeholder Relations, Medicines for Europe

Kate is the Head of Communications and Stakeholder Relations at Medicines for Europe, the trade association representing the generic, biosimilar and value-added medicines industry. Kate joined Medicines for Europe in 2017 after a number of years at the Association of European Cancer Leagues. Having worked more than ten years in the healthcare sector from within the European Parliament, industry, civil society NGO and trade association, Kate is a firm believer in the importance of European policy in boosting access to medicines.



Prof Derek O'Keeffe, Physicianeer, Consultant Clinician/Surgeon (inv)

Prof Derek O'Keeffe is a Physicianeer, who holds dual first-class honors degrees and doctorates in Medicine and Engineering. In addition he holds several gold medal awards across STEM and a first-class honors MBA degree. He was a Fulbright Scholar at Harvard, a Green Templeton Scholar at Oxford and is a graduate of the Endocrinology Clinical Fellowship at the Mayo Clinic, USA. He has multiple academic publications, biomedical patents and several international research prizes. He has previously worked with NASA placing a sleep experiment onboard the International Space Station and was their flight surgeon for a NEEMO Aquarius mission. He is founder and director of the Health Innovation via Engineering (HIVE) Lab which develops patient centred solutions to clinical problems from bedside to bench to bedside through interdisciplinary collaboration. He has explored over 100 countries, volunteered extensively & was awarded The Outstanding Young Person of the World by Junior Chamber International. He is a Black Belt Taekwondo Instructor, Qualified Pilot, DJ, Advanced Scuba Diver, Triathlete & Six-Star Medal Marathoner. He has designed an award winning Cardiovascular themed garden for Bloom in the Phoenix Park and is a Guinness World Record Holder. He is a Consultant Physician (Endocrinologist) at University Hospital Galway and is the Professor of Medical Device Technology at the University of Galway. He is currently the HSE National Clinical Lead for Diabetes.



James Burt, Chair of Value Added Medicines Sector Group, CEO of Pharmanovia

James joined Pharmanovia in October 2021. Before joining he was the Executive Vice President EMENA at Accord Healthcare and oversaw branded and generic pharmaceutical activities across 65 markets. Prior to this, he served as Vice President Hospital Business at Actavis, where he was responsible for the strategic direction of secondary-care activities worldwide. He holds a PhD in Chemical Engineering from the University of Birmingham, with a particular focus on biopharmaceutical manufacturing. James is Chair of the Medicines for Europe, Value Added Medicines Sector Group.



Stefano Collatina, Country Lead, Italy and Pharmaceuticals Business Unit Head Southern Europe, Baxter

Stefano is a Physician and Manager in the Healthcare sector. His experiences are at the intersection between medicine, technology, and the management of complex organizations. Since 2019, Stefano has been Country Lead of Baxter S.p.A., the Italian subsidiary of Baxter Healthcare, a global leader in the Pharmaceutical and MedTech sector, with a turnover of \$15 billion and 60,000 employees. In Baxter, Stefano also holds the role of Head of the Pharmaceutical Business Unit for Central and South Europe, with business responsibility for the main European markets (Italy, France, Spain, Portugal, Greece, and Benelux). In the last 14 years at Baxter, Stefano has held management positions in Italy and in other

European countries, including Market Access & Institutional Relations; Patient support Programs; Operations; Hospital Division Head; Integrated Care Solutions & Digital Health. In all positions, he has consistently met or exceeded budget and revenue targets. Before Baxter, Stefano worked in Bristol-Myers Squibb, both in Italy, as Medical Director (he was involved, among other things, in the development of innovative drugs in the cardiology and internal medicine area), and in the USA, as Medical- Marketing Director. Subsequently, he served as Medical Director for Merck Sharpe & Dohme and as Business Unit Director for Schering AG where he gathered extensive experience in Multiple Sclerosis and related patient support programs. At the institutional level, Stefano represents Baxter Healthcare in Italy and in Europe. Stefano is the President of EGUALIA, an association of Pharmaceutical Industries that brings together 70 companies of generic medicines and Biosimilars.



Lisa Wynne, Parkinson's Nurse Specialist, a member of the Parkinson's Europe Research Steering Group and a member of Parkinson's Ireland

Lisa is an accomplished Parkinson's Nurse Specialist with over a decade of experience, pivotal in shaping Parkinson's Ireland's nurse service. Her approach emphasizes empowerment and education through initiatives like public lectures and online seminars. She's dedicated to raising awareness and dispelling misconceptions about Parkinson's through media engagement. Lisa's international collaborations advance PD research and treatment modalities. As Vice Chairperson of the Research & Impact Subcommittee of PI, she drives critical research agendas. Her recent completion of a CPD module reflects her commitment to staying current in PD care. Lisa's contributions have significantly improved support and resources for those affected by Parkinson's in Ireland and globally.



Silke Oeschger-Delautre, Corporate Communication Lead, Dr. Reddy's



Keith Moore, Programme Coordinator, Sustainable Healthcare Coalition

Keith Moore is an established environmental and sustainability professional with over 25 years' experience. Before taking up the role of Programme Coordinator at Sustainable Healthcare Coalition, he was AstraZeneca's lead on carbon and climate strategy helping the company achieve "A-list" on the CDP annual corporate benchmarking programme and inclusion in both the FTSE4Good and Dow Jones Sustainability Indices. The Sustainable Healthcare Coalition is a healthcare sector led group that looks for the greatest opportunities to inspire sustainable practices in healthcare through the collaboration of its members.



Courtney Soulsby, Global Director Healthcare and Life Sciences Sector, BSI

Courtney Soulsby works as a Global Director for the Healthcare and Life Sciences sector team for BSI (British Standards Institution). Working to understanding market challenges and future needs of the healthcare sector, Courtney works with key clients and industry partners to develop holistic solutions, strategies and programs. Courtney has worked with pharmaceutical industry and their downstream logistics supply chain for over ten years – with a deep understanding the issues with regulation, compliance, quality, and other risk exposures when transporting medicines.



Ines Windisch, Head of Communications, Corporate Affairs & Sustainability, Zentiva Group

Recognized as a highly experienced leader who spent almost 30 years in the healthcare industry in various areas like Communications, Corporate Affairs, Marketing & Sales, Market Access, Human Resources and Sustainability, locally, regionally and globally. While focusing on change management, organizational excellence, and stakeholder management I have proven performance in successful integration and transformation projects in small startups and in larger organizations. I am engaging the targeted community with drive, passion, creativity, and personalized communication. Strong track record in building teams, strengthening corporate culture and identity, and transforming organizations from good to great. During the last 6 years I am part of the exciting journey at Zentiva that started with the carve out from Sanofi. Together with 5000 colleagues across Europe and in India we have doubled the company, strengthened our resilience and are enjoying our time together in a great place to work. I am passionate about making a difference by engaging people to take better care of our impact on the society and our planet. In my private life I am a proud Austrian, who has decided to live in the most beautiful place on earth, enjoying my free time with my family discovering our beautiful nature.



Maja Anette Flønes Monsen, Norwegian Hospital Procurement Fund, Skyehusinnkop

Maja Anette Flønes Monsen is an experienced pharmacist, creative author, and poet. She is currently working for the Norwegian hospital procurement trust, where she, in the last seven years, has had a leading role in including environmental criteria in medicines tenders in Norway and the Nordic countries. Her responsibility has been to provide the best agreements for a total of 90% of the medicines daily used in Norwegian hospitals. The inclusion of environmental criteria arrived both from a need for change in the long-term strategic planning to secure the supply chain, and from a governmental focus on combating antibiotic resistance and changing environmental impact.

Maja has written, tested, evaluated, and scored different environmental criteria on a large scale, over a big range of different medicines and suppliers. The work has given her a unique insight and expertise in how to drive changes, and approach sustainability in the tender process for medicines.



Pierluigi Antonelli, President and CEO, Fresenius Kabi

Pierluigi Antonelli is the President and CEO of Fresenius Kabi since March 2023. He has extensive operational expertise in the healthcare industry, with a focus on product development, launch of new products in key international markets, business & strategy development. In his previous position, he served as CEO of Angelini Pharma, a company specialized in Brain Health and Consumer Health, since 2019. Prior to that, he held senior positions at companies such as Novartis Oncology, Sandoz, Merck & Co, and Bristol-Myers Squibb in the United States and Europe, after working few years in McKinsey & Company. He holds an MBA from Kellogg School of Management and a degree in Economics from L.U.I.S.S..



Markus Sieger, CEO, Polpharma Group

Markus Sieger has been active in emerging markets and emerging industries for over 30 years. During this time, he has focused on building and developing companies in the pharmaceutical, media, fast-moving consumer goods and real estate industries, by managing complex and strategic transactions in the USA, CEE, CIS and Singapore. He has been a member of supervisory boards of private and public companies and is currently the chairman of Cyclo Therapeutics (NASDAQ:CYTH). He has been associated with Polpharma Group since 2000 and was appointed CEO of Polpharma Group in June 2016. In 2018, he joined the Executive Committee of Medicines for Europe. He is an alumnus of Stanford University Graduate School of Business.



Rebecca Guntern, President Europe, Sandoz

Rebecca Guntern is the president of Sandoz Europe and member of the executive committee. Region Europe spans across more than 40 countries on the continent and delivered sales in 2023 of 5 bn USD. She is a senior business leader with over 25 years of international experience in the pharmaceutical and healthcare industry. She joined Sandoz in 2007 as Head of Sales and has held positions of increasing leadership responsibility since then. Prior to joining Sandoz, Rebecca Guntern worked for other leading pharmaceutical companies such as Roche and Merck Sharpe & Dohme. Rebecca Guntern serves as vice president of Medicines for Europe (MfE) and is a member of the board of directors at BKW AG Switzerland, where she is heading the compensation committee. She holds a master's degree in pharmacy from the University of Basel as well as a bachelor's degree in business administration.



Stephan Eder, Executive Vice President Western Europe & Germany, STADA



Artur Cwiok, Head of Europe, Viatris

Artur Cwiok has over 31 years experience in the pharmaceutical industry. He has held senior leadership roles across Europe, leading in the innovative specialty sector and across all channels: generics, brands, OTC, retail, and hospital. Dr. Cwiok is currently serving as the Head of Europe for Viatris, one of the world's leading global pharmaceutical companies, empowering people worldwide to live healthier at every stage of life. Viatris is present in 38 countries in the European region and in more than 165 countries and territories globally. Dr. Cwiok actively represents his company in national and regional industry associations, helping shape policies that enable the European population to have access to high quality medicine. He is currently serving as a Member of the Executive Committee for Medicines for Europe. Dr. Cwiok is passionate about providing universal access to medicine and giving everyone the opportunity to live the healthiest life possible.



Steffen Saltofte, CEO, Zentiva



Adrian van den Hoven, Director General, Medicines for Europe

Adrian van den Hoven has been director general of Medicines for Europe since September 2013. In his role he focuses on stimulating competition in off-patent medicine markets, fostering access to medicine, reducing medicine shortages and addressing major health crises, supporting policy measures for sustainable pricing, promoting efficient regulatory standards, and developing a coherent EU industrial strategy to support the long-term viability of the generic, biosimilar and value-added medicines industries. He is also member, and former president, of the European Medicines Verification Organization (EMVO) board for the implementation of serialization against falsified medicines, the Chair of the International Generic and Biosimilar medicines Association (IGBA) and a member of the joint industry advisory council of the Health Emergency and Response Authority (HERA).